Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — Investor Presentation (July 2021)
39 slides from Lumos Diagnostics's investor presentation, Jul 8, 2021
Slide 1: ASX Announcement: Investor Presentation
ASX ANNOUNCEMENT 8 JULY 2021 INVESTOR PRESENTATION For personal use only MELBOURNE, Australia (8 July 2021): Lumos Diagnostics Holdings Limited (ASX:LDX, ‘Lumos’ or the ‘Company’), a leader in rapid diagnostic test technology, is pleased to release the attached Investor Presentation. < ENDS > Author
Slide 2: Lumos Diagnostics Investor Briefing July 2021
For personal use only Lumos Diagnostics Investor Briefing July 2021 NOT FOR RELEASE TO U.S. WIRE SERVICES OR FOR DISTRIBUTION IN THE UNITED STATES www.lumosdiagnostics.com
Slide 3: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company). For personal use only NOT BE RELEASED TO US WIRE SERVICES OR DISTRIBUTED IN THE UNITED STATES: This Presentation has been prepare
Slide 4: Business Summary
Business Summary • Comprehensive point-of-care (POC) diagnostic test, digital test-reader, and automated test manufacturing capability across both: For personal use only − Products - development, manufacture and sale of its own, proprietary and in-licensed POC diagnostic tests − Commercial Services
Slide 5: Investment Highlights
Investment Highlights For personal use only A leading end-to-end provider of POC diagnostic tests and development services from initial diagnostic assay and reader development through 1 to high-volume manufacturing of commercial product Lumos’ Commercial Services business has grown rapidly deliverin
Slide 6: Lumos Diagnostics
For personal use only Lumos Diagnostics NOT FOR RELEASE TO U.S. WIRE SERVICES OR FOR DISTRIBUTION IN THE UNITED STATES 5 © Lumos Diagnostics, all rights reserved
Slide 7: Lumos at a Glance
Lumos at a Glance For personal use only Fully integrated developer and manufacturer of POC $23.8m FY21F revenue diagnostic tests, digital test-readers and automated test • Growth of 109% CAGR1 manufacturing across: FebriDx®: 99% Negative Predictive Value • Products - development, manufacture and sal
Slide 8: Lumos Business Overview
Lumos Business Overview Lumos has a comprehensive POC capability from initial assay development through to high-volume manufacturing For personal use only which is used to develop its own tests for sale and for clients under commercial contracts PRODUCTS COMMERCIAL SERVICES FebriDx® Other products D
Slide 9: Proprietary Readers: Different Settings
Proprietary Readers: Different Settings Lumos is developing a comprehensive digital reader platform designed to satisfy the specific needs of different For personal use only customer groups SINGLE-USE DISPOSABLE MULTI-USE DISPOSABLE DESKTOP • Single use disposable tests • 10-50 single use test strip
Slide 10: POC Diagnostic Tests: Large Addressable Markets
POC Diagnostic Tests: Large Addressable Markets Lumos is currently focused on the development and commercialisation of POC diagnostic tests for infectious For personal use only diseases in the North American and European markets 2020e POC Diagnostic Tests Global Sales by POC Diagnostic Tests Global
Slide 11: Strong Macro Growth Drivers
Strong Macro Growth Drivers Long term growth for the POC diagnostic test market driven by technology advances, decentralisation of For personal use only healthcare services and increased prevalence of medical conditions that require testing Selected Growth Drivers Impact of COVID-19 on POC diagnosti
Slide 12: Capabilities
For personal use only Capabilities NOT FOR RELEASE TO U.S. WIRE SERVICES OR FOR DISTRIBUTION IN THE UNITED STATES 11 © Lumos Diagnostics, all rights reserved
Slide 13: Overuse of Antibiotics
Overuse of Antibiotics Extensive inappropriate use of antibiotics is adversely impacting healthcare through the emergence of antimicrobial For personal use only resistance, adverse side effects and increased costs to healthcare systems Diagnostic uncertainty Healthcare providers unable to determine
Slide 14: FebriDx: A Simple Test For Microbial Infection
FebriDx®: A Simple Test For Microbial Infection FebriDx® can rapidly identify patients who have a microbial infection1 and, if positive, determine if that infection is For personal use only caused by a viral or bacterial pathogen BACTERIAL INFECTION VIRAL INFECTION VIRAL INFECTION Key: Markers for i
Slide 15: FebriDx: Essential Part of A Doctor's Diagnostics Toolkit
FebriDx®: Essential Part of A Doctor’s Diagnostics Toolkit Often difficult for clinicians to distinguish between viral and bacterial infections based on patient symptoms alone. For personal use only FebriDx® has the potential to become an essential part of a doctor’s diagnostics toolkit Unmet diagno
Slide 16: FebriDx is Used in a Range of Settings
FebriDx® is Used in a Range of Settings The FebriDx® test’s initial target markets include its use during consultations in primary care, triage in hospitals and For personal use only emergency departments, and at-home self-assessment Outpatient Inpatient Homecare primary and urgent care hospitals /
Slide 17: Potential Benefits of FebriDx
Potential Benefits of FebriDx® FebriDx® can deliver significant tangible benefits to patients and across the health system For personal use only Patients Physicians Insurers and Government ü Reduce incidence of side effects ü Greater confidence on treatment ü Reduce antimicrobial resistance caused b
Slide 18: FebriDx: Confidence in Highly Accurate Results
FebriDx®: Confidence in Highly Accurate Results High negative predictive value, sensitivity and specificity demonstrated in multiple clinical trials For personal use only • 99% certainty that a patient FebriDx® has been tested on does not have a bacterial 1,982 patients over nine infection (and ther
Slide 19: FebriDx Path to Market and Total Addressable Market
FebriDx® Path to Market and Total Addressable Market FebriDx has regulatory clearance in the UK, Germany, and Canada and has commenced commercialisation.1 For personal use only In the US, a 510(k) application has been lodged with the FDA and is currently under review. Status Status / Strategy Total
Slide 20: Commercial Services
For personal use only Commercial Services NOT FOR RELEASE TO U.S. WIRE SERVICES OR FOR DISTRIBUTION IN THE UNITED STATES 19 © Lumos Diagnostics, all rights reserved
Slide 21: Lumos Commercial Services
Lumos Commercial Services Lumos’ commercial services business provides clients with a complete, end-to-end POC solution For personal use only CHEMISTRY ENGINEERING PRODUCTION Assay Development1 Reader Customisation Manufacturing Development of robust POC Integration of POC diagnostic tests into read
Slide 22: Facilities, Quality and Manufacturing
Facilities, Quality and Manufacturing High quality manufacturing facilities in place with excess capacity and headroom to underpin significant growth in For personal use only contract revenue and for manufacture of Lumos’ own proprietary products Capable of manufacturing ~120M+ tests per annum by mi
Slide 23: Corporate Overview
For personal use only Corporate Overview NOT FOR RELEASE TO U.S. WIRE SERVICES OR FOR DISTRIBUTION IN THE UNITED STATES 22 © Lumos Diagnostics, all rights reserved
Slide 24: Patents and Significant Regulatory Requirements
Patents and Significant Regulatory Requirements Lumos possesses significant competitive strengths, driven by its proprietary products and its commercial services For personal use only businesses • 461 existing patents granted or exclusively in-licensed, with 341 pending INTELLECTUAL 1 PROPERTY • Mul
Slide 25: Board of Directors & Select Senior Management
Board of Directors & Select Senior Management Led by a management team with strong technical and commercial experience and a track record working together For personal use only Sam Lanyon Executive Chairperson Rob Sambursky Melanie Leydin Paul Kase 25+ years in business strategy, CEO and Board Membe
Slide 26: Target Milestones and Strategies
Target Milestones and Strategies Lumos has a range of target milestones over 2021 and strategies over the medium term to drive growth For personal use only CY2021 targets Selected medium term strategies • FebriDx®: FDA approval • FebriDx®: Launch of multi-use re-useable & disposable • Completion of
Slide 27: Financials
For personal use only Financials NOT FOR RELEASE TO U.S. WIRE SERVICES OR FOR DISTRIBUTION IN THE UNITED STATES 26 © Lumos Diagnostics, all rights reserved
Slide 28: Lumos Strong Growth Trajectory
Lumos Strong Growth Trajectory Lumos is experiencing significant revenue growth across both its Products and Commercial Services business divisions For personal use only Pro Forma Revenue Growth (A$M) 30.0 115.0% 25.0 23.8 95.0% 20.0 75.0% nue 9% Reve 10 R 15.0 CAG 55.0% 47.3% 20.9 37.9% 34.9% 10.0
Slide 29: Pro Forma Profit and Loss Statement
Pro Forma Profit and Loss Statement Summary Pro forma historical results and pro forma For personal use only Key operating metrics Commentary forecast A$ millions Notes FY19 FY20 FY21F % Notes FY19 FY20 FY21F • Revenue growth of 183% forecast in FY21 Product revenue 0.2 0.5 2.9 Pro forma revenue gro
Slide 30: Pro Forma Cash Flows
Pro Forma Cash Flows For personal use only Consolidated Pro Forma Historical Cash Flows, Pro Forma Forecast Cash Flows Commentary A$ millions Notes FY19 FY20 FY21F • Increased capital expenditure represents investment in new EBITDA before non-operating items (11.1) (17.7) (14.6) Sarasota, Florida fa
Slide 31: Pro Forma Balance Sheet
Pro Forma Balance Sheet Statutory Historical Statement of Financial Position and Pro Forma Statement of Financial Position as For personal use only Commentary at 31 December 2020 Interest on Pre- Pre-IPO Statutory 31 Preference Share Repayment of Impact of the Pro Forma 31 A$ millions December 2020
Slide 32: www.lumosdiagnostics.com
For personal use only www.lumosdiagnostics.com
Slide 33: Appendix
For personal use only Appendix NOT FOR RELEASE TO U.S. WIRE SERVICES OR FOR DISTRIBUTION IN THE UNITED STATES 32 © Lumos Diagnostics, all rights reserved
Slide 34: Company History
Company History For personal use only 2017 2004 Divested RPS Founded in ophthalmology Sarasota, FL business 2019 Lumos Diagnostics merges with RPS 2010 2015 2016 2017 2017 Planet Innovation PI acquires PI and Nplex Nplex acquires Lumos Diagnostics (PI) Founded Nplex develop first Kestrel rebranded c
Slide 35: Key Risks
Key Risks Key risks1 For personal use only For each country in which Lumos wishes to distribute its Products, Lumos will be required to obtain product clearances or approvals prior to marketing the product and is required to maintain an up to date product registration with appropriate governmental a
Slide 36: Key Risks (cont.)
Key Risks (cont.) Key risks For personal use only Lumos has operated at a loss since its incorporation. In the financial year ended 30 June 2020, Lumos had net losses of $13.5 million. Please refer to Section 4 of the recent Prospectus. Lumos anticipates that its operating expenses will continue to
Slide 37: Key Risks (cont.)
Key Risks (cont.) Key risks For personal use only Lumos operates in a competitive market against a number of other diagnostic technology companies, with the market being further disrupted by new technologies and products introduced as a result of the COVID-19 pandemic and the increased demand for di
Slide 38: Key Risks (cont.)
Key Risks (cont.) Key risks For personal use only Lumos currently conducts the majority of its business in the United States with a majority of costs denominated in foreign currency (most notably USD). As such, unhedged, unfavourable movements in the Currency movements may be exchange rate between t
Slide 39: Key Risks (cont.)
Key Risks (cont.) Key risks For personal use only Stock market conditions may affect the value of Lumos’ quoted securities regardless of Lumos’ operating performance. These conditions may cause the Shares to trade at prices below the price at which the Shares are being offered under the recent Prosp
Lumos Diagnostics Holdings — Investor Presentation (July 2021) on 6ix